The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
Joseph ChenHuiping XuSylvester PawlakLeonard P JamesGerson PeltzKimberly LeeKatherine GinmanMichelle BergeronYazdi K PithavalaPublished in: Advances in therapy (2019)
ClinicalTrials.gov identifier, NCT02804399.